2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce density
2014
Central IKKβ inhibition prevents air pollution mediated peripheral inflammation and exaggeration of type II diabetes
Liu C, Fonken L, Wang A, Maiseyeu A, Bai Y, Wang T, Maurya S, Ko Y, Periasamy M, Dvonch T, Morishita M, Brook R, Harkema J, Ying Z, Mukherjee B, Sun Q, Nelson R, Rajagopalan S. Central IKKβ inhibition prevents air pollution mediated peripheral inflammation and exaggeration of type II diabetes. Particle And Fibre Toxicology 2014, 11: 53. PMID: 25358444, PMCID: PMC4226918, DOI: 10.1186/s12989-014-0053-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAnti-Inflammatory AgentsBenzamidesBlood GlucoseDiabetes Mellitus, Type 2Disease Models, AnimalEnergy MetabolismHypothalamusI-kappa B KinaseInflammationInfliximabInhalation ExposureInjections, IntraventricularInsulinInsulin ResistanceInterleukin-6MiceOxygen ConsumptionParticulate MatterProtein Kinase InhibitorsRisk AssessmentRNA, MessengerThermogenesisTime FactorsTumor Necrosis Factor-alpha